Dewi Susanna1, Dian Pratiwi2, Sang Gede Purnama3,4. 1. Department of Environmental Health, Faculty of Public Health, Universitas Indonesia, Depok, Jawa Barat, 16424, Indonesia. 2. Alumni of Faculty of Public Health, Universitas Indonesia, Depok, Jawa Barat, 16424, Indonesia. 3. Faculty of Medicine, Udayana University, Denpasar, Bali, 80234., Indonesia. 4. Doctoral Program in Faculty of Public Health, Universitas Indonesia, Depok, Jawa Barat, 16424, Indonesia.
Abstract
Background: Mass testing and adequate management are essential to terminate the spread of coronavirus disease 2019 (COVID-19). This testing is due to the possibility of unidentified cases, especially ones without COVID-19 related symptoms. This review aimed to examine the outcome of the existing studies on the ways of identifying COVID-19 cases, and determine the populations at risk, symptom and diagnostic test management of COVID-19. Methods: The articles reviewed were scientific publications on the PubMed, Science Direct, ProQuest, and Scopus databases. The keywords used to obtain the data were COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and case detection, case management or diagnostic test. We applied the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Population, Intervention, Control and Outcomes (PICO) approaches. Results: A total of 21 articles from 13 countries met the inclusion criteria and were further analyzed qualitatively. However, 62% of the articles used a rapid antibody test for screening rather than a rapid antigen test. According to the rapid antigen test, 51.3% were positive, with men aged above 50 years recording the highest number of cases. Furthermore, 57.1% of patients were symptomatic, while diagnostic tests' sensitivity and specificity increased to 100% in 14 days after the onset. Conclusion s: Real-time polymerase chain reaction (RT-PCR) is recommended by the World Health Organization for detection of COVID-19. Suppose it is unavailable, the rapid antigen test is used as an alternative rather than the rapid antibody test. Diagnosis is expected to be confirmed using the PCR and serological assay to achieve an early diagnosis of COVID-19, according to disease progression, gradual rapid tests can be used, such as rapid antigen in an earlier week and antibody tests confirmed by RT-PCR and serological assay in the second week of COVID-19. Copyright:
Background: Mass testing and adequate management are essential to terminate the spread of coronavirus disease 2019 (COVID-19). This testing is due to the possibility of unidentified cases, especially ones without COVID-19 related symptoms. This review aimed to examine the outcome of the existing studies on the ways of identifying COVID-19 cases, and determine the populations at risk, symptom and diagnostic test management of COVID-19. Methods: The articles reviewed were scientific publications on the PubMed, Science Direct, ProQuest, and Scopus databases. The keywords used to obtain the data were COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and case detection, case management or diagnostic test. We applied the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Population, Intervention, Control and Outcomes (PICO) approaches. Results: A total of 21 articles from 13 countries met the inclusion criteria and were further analyzed qualitatively. However, 62% of the articles used a rapid antibody test for screening rather than a rapid antigen test. According to the rapid antigen test, 51.3% were positive, with men aged above 50 years recording the highest number of cases. Furthermore, 57.1% of patients were symptomatic, while diagnostic tests' sensitivity and specificity increased to 100% in 14 days after the onset. Conclusion s: Real-time polymerase chain reaction (RT-PCR) is recommended by the World Health Organization for detection of COVID-19. Suppose it is unavailable, the rapid antigen test is used as an alternative rather than the rapid antibody test. Diagnosis is expected to be confirmed using the PCR and serological assay to achieve an early diagnosis of COVID-19, according to disease progression, gradual rapid tests can be used, such as rapid antigen in an earlier week and antibody tests confirmed by RT-PCR and serological assay in the second week of COVID-19. Copyright:
Authors: Alison C Roxby; Alexander L Greninger; Kelly M Hatfield; John B Lynch; Timothy H Dellit; Allison James; Joanne Taylor; Libby C Page; Anne Kimball; Melissa Arons; Laura A Schieve; Albert Munanga; Nimalie Stone; John A Jernigan; Sujan C Reddy; James Lewis; Seth A Cohen; Keith R Jerome; Jeffrey S Duchin; Santiago Neme Journal: MMWR Morb Mortal Wkly Rep Date: 2020-04-10 Impact factor: 17.586
Authors: Jaime de la Iglesia; Tania Fernández-Villa; Juan M Fegeneda-Grandes; Manuel Gómez-García; Raúl Majo García; Silvia López Sanz; Patricia Mendez da Cuña; Marta Llaneza García; Alicia Marcos Sádaba; José Pedro Fernández Vázquez Journal: Semergen Date: 2020-06-17
Authors: M Döhla; C Boesecke; B Schulte; C Diegmann; E Sib; E Richter; M Eschbach-Bludau; S Aldabbagh; B Marx; A-M Eis-Hübinger; R M Schmithausen; H Streeck Journal: Public Health Date: 2020-04-18 Impact factor: 2.427